このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

MCRPCの被験者におけるアカパタマブの安全性、忍容性、薬物動態、および有効性

2026年8月19日 更新者:Amgen

転移性去勢抵抗性前立腺癌患者における前立腺特異的膜抗原半減期の延長された二重特異性 T 細胞エンゲージャー Acapatamab の安全性、忍容性、薬物動態、および有効性を評価する第 1 相試験

A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

調査の概要

詳細な説明

This is a phase I, first-in-human study to evaluate the safety and tolerability of acapatamab; a half-life extended (HLE) bispecific T-cell engager (BiTE®) construct, alone and in combination with pembrolizumab, etanercept prophylaxis and cytochrome P450 (CYP) phenotyping cocktail in subjects with metastatic castration-resistant prostate cancer.

研究の種類

介入

入学 (実際)

212

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Campbell、California、アメリカ、95008
        • El Camino Hospital
      • Duarte、California、アメリカ、91010
        • City of Hope National Medical Center
      • Long Beach、California、アメリカ、90813
        • City of Hope at Long Beach Elm
      • Los Angeles、California、アメリカ、90095
        • University of California Los Angeles
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • Emory University
    • Indiana
      • Indianapolis、Indiana、アメリカ、46202
        • Indiana University
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • University of Iowa Hospitals and Clinics
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70112
        • Tulane Medical Center
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • Washington University
    • Nevada
      • Las Vegas、Nevada、アメリカ、89169
        • Comprehensive Cancer Centers of Nevada
    • New York
      • New York、New York、アメリカ、10065
        • Weill Cornell Medical College
      • New York、New York、アメリカ、10065
        • Memorial Sloan Kettering Cancer Center
    • Texas
      • Dallas、Texas、アメリカ、75390
        • University of Texas Southwestern Medical Center
      • Rotterdam、オランダ、3015 GD
        • Erasmus Medisch Centrum
    • New South Wales
      • Camperdown、New South Wales、オーストラリア、2050
        • Chris OBrien Lifehouse
      • Randwick、New South Wales、オーストラリア、2031
        • Scientia Clinical Research Ltd
    • Victoria
      • Parkville、Victoria、オーストラリア、3050
        • Peter MacCallum Cancer Centre
      • Linz、オーストリア、4020
        • Ordensklinikum Linz Elisabethinen
      • Salzburg、オーストリア、5020
        • Landeskrankenhaus Salzburg
      • Vienna、オーストリア、1090
        • Universitaetsklinikum Allgemeines Krankenhaus Wien
      • Vienna、オーストリア、1020
        • Krankenhaus der Barmherzigen Brueder Wien
    • British Columbia
      • Vancouver、British Columbia、カナダ、V5Z 4E6
        • BC Cancer Vancouver
      • Singapore、シンガポール、119074
        • National University Hospital
      • Singapore、シンガポール、169610
        • National Cancer Centre Singapore
      • Villejuif、フランス、94805
        • Institut Gustave Roussy
      • Brussels、ベルギー、1200
        • Universite Catholique de Louvain Cliniques Universitaires Saint Luc
      • Ghent、ベルギー、9000
        • Universitair Ziekenhuis Gent
      • Taoyuan、台湾、33305
        • Linkou Chang Gung Memorial Hospital of Chang Gung Medical Foundation
    • Chiba
      • Kashiwa-shi、Chiba、日本、277-8577
        • National Cancer Center Hospital East
    • Kanagawa
      • Yokohama、Kanagawa、日本、232-0024
        • Yokohama City University Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

男

説明

All Parts

Inclusion Criteria:

  • Subject has provided informed consent prior to initiation of any study specific activities/procedures
  • Subjects with histologically or cytologically confirmed mCRPC who are refractory to a novel antiandrogen therapy (abiraterone, enzalutamide, and/or apalutamide) and have failed at least 1 (but not more than 2) taxane regimens (or who are deemed medically unsuitable to be treated with a taxane regimen or have actively refused treatment with a taxane regimen). Progression on novel antiandrogen therapy may have occurred in the non-metastatic CRPC setting
  • Subjects must have undergone bilateral orchiectomy or must be on continuous ADT with a gonadotropin releasing hormone (GnRH) agonist or antagonist
  • Total serum testosterone </= 50 ng/dL or 1.7 nmol/L
  • Evidence of progressive disease, defined as 1 or more PCWG3 criteria:
  • PSA level >/= 1 ng/mL that has increased on at least 2 successive occasions at least 1 week apart
  • nodal or visceral progression as defined by RECIST 1.1 with PCGW3 modifications
  • appearance of 2 or more new lesions in bone scan
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
  • Life expectancy >/= 6months

Exclusion Criteria:

  • Any anticancer therapy or immunotherapy within 4 weeks of start of first dose, not including luteinizing hormone-releasing hormone agonist (LHRH)/GnRH analogue (agonist/antagonist). Subjects on a stable bisophosphonate or denosumab regimen for >/= 30 days prior to randomization are eligible
  • Prior PSMA-targeted therapy (subjects on prior therapy may be eligible if discussed with Amgen medical monitor prior to enrollment)
  • Central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression
  • Active autoimmune disease or any other diseases requiring immunosuppressive therapy while on study
  • Needing chronic systemic corticosteroid therapy (prednisone > 10 mg per day or equivalent) or any other immunosuppressive therapies (including anti-tumor necrosis factor alpha [TNF alpha] therapies) unless stopped 7 days prior to start of first dose
  • Myocardial infarction, unstable angina, cardiac arrhythmia requiring medication, and/or symptomatic congestive heart failure (New York Heart Association > class II) within 12 months of first dose of acapatamab

Part 2 only:

  • Subjects on a prior PD-1 or PD-L1 inhibitor who experienced a Grade 3 or higher immune-related adverse event prior to first day of dosing
  • History or evidence of interstitial lung disease or active, non-infectious pneumonitis

Part 3 only:

- Evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of investigational product

Part 6 only:

Subjects are excluded from this cohort if any of the following additional criteria apply:

  • Subjects taking strong OAT3 inhibitors (eg, probenecid) or adjust the dosing to 1 mg PO QD.
  • Subjects with latent or active tuberculosis at screening

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:非ランダム化
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part 1 Dose-exploration: acapatamab treatment

Part 1 dose-exploration: acapatamab is administered intravenously. The dose-exploration phase of the study will estimate the MTD of acapatamab. RP2D may be identified based on emerging safety, efficacy, and pharmacodynamic data prior to reaching an MTD.

Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

他の名前:
  • PSMA標的療法
実験的:Part 1 Dose-expansion: acapatamab treatment

Part 1 dose-expansion: acapatamab is administered intravenously at the MTD/RP2D.

Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

他の名前:
  • PSMA標的療法
実験的:Part 2: acapatamab + Pembrolizumab

Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously.

Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

他の名前:
  • PSMA標的療法

Combined with acapatamab for investigational treatment of mCRPC

他の名前:
  • PD-1阻害剤
実験的:Part 3: acapatamab + Etanercept Prophylaxis

Part 3: acapatamab is administered intravenously at RP2D/MTD levels. Etanercept will be administered subcutaneously in cycle 1 only.

Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

他の名前:
  • PSMA標的療法

Prophylaxis for acapatamab-related cytokine release syndrome.

他の名前:
  • TNF-α阻害剤
実験的:Part 4: acapatamab 24 Hour Monitoring

Part 4: acapatamab is administered intravenously at RP2D/MTD with 24-hour monitoring.

Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

他の名前:
  • PSMA標的療法
実験的:Part 5: acapatamab Outpatient Cohort

Part 5: acapatamab is administered intravenously at RP2D/MTD in an outpatient setting with 8-hour monitoring.

Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

他の名前:
  • PSMA標的療法
実験的:Part 6: acapatamab + Cytochrome P450 (CYP) Cocktail Drug Interaction

Part 6: acapatamab is administered intravenously at RP2D/MTD. A CYP phenotyping cocktail will be administered orally.

Investigational immunotherapy for the treatment of metastatic castration-resistant prostate cancer

他の名前:
  • PSMA標的療法

Evaluate the effect of co-administration of multiple dosing of acapatamab on plasma

他の名前:
  • Cooperstown 5+1 CYP フェノタイピング カクテル

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With a Dose Limiting Toxicity (DLT)- Parts 1 and 2
時間枠:Day 1 to 28 of Cycle 1 (length of cycle is 28 days)

DLTs are defined as any adverse event with an onset within first 28 days following first dose of AMG 160 monotherapy (Part 1) or in combination with pembrolizumab (Part 2) with any of the following criteria unless clearly attributable to causes other than AMG 160 treatment: • grade 5 toxicity (eg, death not due to disease progression)

Day 1 to 28 of Cycle 1 (length of cycle is 28 days)
Number of Participants With Treatment Emergent Adverse Events- Parts 1, 2, 3, 4, and 5
時間枠:Up to 30 days after the last dose of study drug, or start of new anti-cancer therapy, whichever occurs first

A treatment-emergent adverse event is one that occurs on or after the first dose of study treatment and up to 30 days after the last dose. Adverse events were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any clinically significant changes in vital signs, electrocardiograms, and clinical laboratory tests were recorded as adverse events.

Up to 30 days after the last dose of study drug, or start of new anti-cancer therapy, whichever occurs first

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective Response (OR) Rate- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

OR was defined as a partial response (PR) or complete response (CR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, confirmed by a repeat assessment at least 4 weeks later. Participants who did not experience a PR/CR or did not have any follow-up tumor assessments were regarded as non-responders.

Up to 3 years
Prostate-specific Antigen (PSA) Response- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

A PSA response (PSA 30) is defined as a ≥ 30% reduction from the baseline PSA, (PSA 50) is defined as a ≥ 50% reduction from the baseline PSA, (PSA 70) is defined as a ≥ 70% reduction from the baseline PSA, and (PSA 90) is defined as a ≥ 90% reduction from the baseline PSA. PSA response must be confirmed by a second consecutive value ≥ 3 weeks later.

Up to 3 years
Duration of Response (DOR)-RECIST 1.1- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

DOR is defined as the time from the date of an initial objective response per RECIST 1.1 to the earlier of progression or death. Participants who had not ended their response at the time of analysis had DOR censored at their last evaluable tumor assessment.

Up to 3 years
Duration of PSA Response- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

PSA DOR is defined as the time from the date of an initial PSA response (PSA 50) to the earlier of PSA progression or death. Subjects who have not ended their response at the time of analysis will have PSA DOR censored on the date of their last PSA measurement. This endpoint only applies to subjects with a PSA response (PSA 50).

Up to 3 years
Percentage of Participants With 68Gallium (68Ga)-Prostate-specific Membrane Antigen (PSMA) Response Parts 1, 2, and 3
時間枠:Up to 3 years

A Gallium PSMA-11 response is a ≥50% reduction from baseline in the maximum standardized uptake value (SUV) using 68Gallium (68Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT).

Up to 3 years
Percentage of Participants With F-fluorodeoxyglucose (FDG) Response- Parts 1, 2, and 3
時間枠:Up to 3 years

A FDG PET response is a ≥50% reduction from baseline in the maximum SUV using 18F-FDG PET/CT.

Up to 3 years
Time to Progression (Radiographic)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

Time to radiographic progression is defined as the time from study Day 1 until the first documentation of radiographic disease progression in the absence of subsequent anticancer therapy. Time to radiographic progression will be censored at the last evaluable post-baseline tumor assessment prior to subsequent anti-cancer therapy; otherwise, at study Day 1.

Up to 3 years
Time to Progression (PSA)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

Time to PSA progression is defined as the interval from study Day 1 to PSA progression; otherwise, time to PSA progression is censored on the date of the last PSA measurement. If a participant has no baseline or no post-baseline PSA measurement, time to PSA progression will be censored at study Day 1.

Up to 3 years
Progression Free Survival (Radiographic)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

Radiographic progression free survival (rPFS) is defined as the interval from study day 1 to the earlier of a radiographic progression or death from any cause; otherwise, rPFS is censored at the last evaluable tumor assessment date. If a subject has no post-baseline radiographic tumor assessment and a vital status of alive or unknown, rPFS will be censored at study day 1.

Up to 3 years
Progression Free Survival (PSA)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

PSA PFS is defined as the interval from study day 1 to the earlier of a PSA progression or death from any cause; otherwise, PSA PFS is censored on the date of the last PSA measurement. If a subject has no baseline or no post-baseline PSA measurement and a vital status of alive or unknown, PSA PFS will be censored at study day 1.

Up to 3 years
Overall Survival- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

Overall survival (OS) is defined as the time from the date of study Day 1 until death due to any cause.

Up to 3 years
Percentage of Participants With Circulating Tumor Cell Response (CTC0)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

CTC0 is defined as reduction of CTCs > 0 to 0 at any post-baseline measurement. CTC0 response is applicable only for participants with baseline CTC > 0.

Up to 3 years
Percentage of Participants With CTC Conversion- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

CTC conversion is defined as ≥ 5 CTCs/7.5 mL blood to ≤ 4 CTCs/7.5 mL blood at any post-baseline measurement. CTC conversion is applicable only for subjects with baseline CTC ≥ 5..

Up to 3 years
Time to Symptomatic Skeletal Events (SSE)- Parts 1, 2, 3, 4, and 5
時間枠:Up to 3 years

Time to SSE is defined as time from study day 1 to the first SSE. Otherwise, SSE is censored at the last dose date of AMG 160 or pembrolizumab or end of safety follow up date, whichever is later.

Up to 3 years
Maximum Observed Concentration (Cmax) of AMG 160 - Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of pharmacokinetic (PK) parameters. Concentrations below the lower limit of quantification (LLOQ) (0.0500 ng/mL) were set to zero before data analysis.

PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
Time to Cmax (Tmax) of AMG 160- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 696 hours)

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis.

Actual time post dose was used for calculations.

PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 696 hours)
Minimum Serum Concentration (Cmin) of AMG 160- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis.

PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
Area Under the Concentration-time Curve (AUC) From Time 0 to Last Quantifiable Concentration (AUClast) of AMG 160- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis.

PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose))
AUC Over the Dosing Interval (AUCtau)- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis.

PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)
Terminal Half-life (t1/2,z) of AMG 160- Parts 1, 2, and 3
時間枠:Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)

Serum concentrations of AMG 160 were determined using a validated assay. Noncompartmental analysis was performed for the estimation of PK parameters. Concentrations below the LLOQ (0.0500 ng/mL) were set to zero before data analysis.

PK parameters, including Cmax, Tmax, Cmin, AUClast, AUCtau, t1/2,z, were not estimated for Parts 4 and 5 because the PK sampling schedule in these parts was sparse and not designed to support parameter estimation.

Cycle 1 Days 1, 8, 15, and 22; Cycle 2 Days 1 and 15 (sampling pre-dose up to 168 hours post-dose)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:MD、Amgen

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年2月5日

一次修了 (実際)

2023年6月29日

研究の完了 (実際)

2023年6月29日

試験登録日

最初に提出

2019年1月2日

QC基準を満たした最初の提出物

2019年1月2日

最初の投稿 (実際)

2019年1月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月10日

QC基準を満たした最後の更新が送信されました

2026年8月19日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

IPD 共有時間枠

Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

IPD 共有アクセス基準

Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する